Atcı Muhammed Mustafa, Geredeli Çağlayan, Ay Seval, Sakin Abdullah, Ertürk Biray, Seçmeler Şaban, Arıcı Serdar, Çekin Ruhper, Yaşar Nurgül, Can Orçun, Cihan Şener, Gümüş Mahmut
Clinic of Medical Oncology, İstanbul Professor Doctor Cemil Tasçıoğlu City Hospital, İstanbul, Turkey.
Department of Medical Oncology, Medeniyet University, Göztepe Training and Research Hospital, İstanbul, Turkey.
Eur J Breast Health. 2021 Mar 31;17(2):123-127. doi: 10.4274/ejbh.galenos.2020.6346. eCollection 2021 Apr.
This study aimed to determine the differences in clinicopathological features of Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer susceptibility genes (BRCA1/2) .
This study enrolled patients with invasive breast cancer who have been evaluated for BRCA1/2 mutations due to the presence of high-risk factors admitted to two tertiary referral centers in Turkey. Clinical and histopathological features were analyzed in BRCA1 mutation carriers, BRCA2 mutation carriers, and non-carriers.
A total of 302 patients with a mean age of 44.2±9.9 (22-82) years were included. BRCA1/2 mutation was found in 75 (24%) patients, of whom 41 (13.6%) were BRCA1 mutation carriers and 37 (12.3%) were BRCA2 mutation carriers. Moreover, 104 (34.4%) and 4 (1.3%) patients had family history of breast and ovarian carcinoma, respectively. The rates of triple negativity (56.1%), histologic grade 3 (65.9%), and lymphovascular invasion (78%) were significantly higher in BRCA1 mutation carriers than in non-carriers and BRCA2 mutation carriers. Furthermore, 87% of triple-negative BRCA1 mutation carriers had histologic grade 3 tumors compared with 38.9% in non-triple-negative BRCA1 mutation carriers, and the difference was significant.
Findings of this study showed that BRCA1-related breast cancers represent a distinct group with unique pathological features, which are usually associated with a poor prognosis.
本研究旨在根据两个乳腺癌易感基因(BRCA1/2)的突变状态,确定土耳其高危乳腺癌患者的临床病理特征差异。
本研究纳入了因存在高危因素而在土耳其两家三级转诊中心接受BRCA1/2突变评估的浸润性乳腺癌患者。对BRCA1突变携带者、BRCA2突变携带者和非携带者的临床和组织病理学特征进行了分析。
共纳入302例患者,平均年龄44.2±9.9(22 - 82)岁。75例(24%)患者检测到BRCA1/2突变,其中41例(13.6%)为BRCA1突变携带者,37例(12.3%)为BRCA2突变携带者。此外,分别有104例(34.4%)和4例(1.3%)患者有乳腺癌和卵巢癌家族史。BRCA1突变携带者的三阴性率(56.1%)、组织学3级率(65.9%)和淋巴管浸润率(78%)显著高于非携带者和BRCA2突变携带者。此外,87%的三阴性BRCA1突变携带者有组织学3级肿瘤,而非三阴性BRCA1突变携带者的这一比例为38.9%,差异有统计学意义。
本研究结果表明,BRCA1相关乳腺癌代表了一个具有独特病理特征的不同群体,通常预后较差。